Show simple item record

dc.contributor.authorParry, M. G.
dc.contributor.authorNossiter, J.
dc.contributor.authorCowling, T. E.
dc.contributor.authorSujenthiran, A.
dc.contributor.authorBerry, B.
dc.contributor.authorCathcart, P.
dc.contributor.authorClarke, Noel W
dc.contributor.authorPayne, H.
dc.contributor.authorvan der Meulen, J.
dc.contributor.authorAggarwal, A.
dc.date.accessioned2020-08-17T07:21:41Z
dc.date.available2020-08-17T07:21:41Z
dc.date.issued2020en
dc.identifier.citationParry MG, Nossiter J, Cowling TE, Sujenthiran A, Berry B, Cathcart P, et al. Toxicity of pelvic lymph node irradiation with intensity modulated radiation therapy for high-risk and locally advanced prostate cancer: a national population-based study using patient-reported outcomes. Int J Radiat Oncol Biol Phys. 2020.en
dc.identifier.pmid32717261en
dc.identifier.doi10.1016/j.ijrobp.2020.07.031en
dc.identifier.urihttp://hdl.handle.net/10541/623203
dc.description.abstractPurpose: Little is known about the toxicity of additional pelvic lymph node irradiation in men receiving intensity-modulated radiotherapy (IMRT) for prostate cancer. The aim of this study was to compare patient-reported outcomes following IMRT to the prostate only (PO-IMRT) versus the prostate and pelvic lymph nodes (PPLN-IMRT). Methods and materials: Patients diagnosed with high-risk or locally advanced prostate cancer in the English National Health Service between April 2014 and September 2016 treated with IMRT were mailed a questionnaire at least 18 months after diagnosis. Patient-reported urinary, sexual, bowel and hormonal functional domains on a scale from 0 to 100 with higher scores indicating better outcomes and generic health-related quality of life were collected using the EPIC-26 and EQ-5D-5L. We used linear regression to compare PPLN-IMRT versus PO-IMRT with adjustment for patient, tumour and treatment characteristics. Results: Of the 7017 men who received a questionnaire, 5468 (77.9%) responded with 4196 (76.7%) having received PO-IMRT and 1272 (23.3%) PPLN-IMRT. Adjusted differences in EPIC-26 domain scores were smaller than 1 (p always >0.2) except for sexual function with men who had PPNL-IMRT reporting a lower mean score (adjusted difference 2.3, 95% confidence interval 0.9 to 3.7; p=0.002), which did not represent a clinically relevant difference. There was no significant difference in HRQoL (p=0.5). Conclusions: Additional pelvic lymph node irradiation does not lead to clinically meaningful increases in the toxicity of IMRT for prostate cancer according to patient-reported functional outcomes and HRQoL. Keywords: Prostate cancer; intensity-modulated radiotherapy; patient-reported outcomes measures; pelvic lymph nodes.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1016/j.ijrobp.2020.07.031en
dc.titleToxicity of pelvic lymph node irradiation with intensity modulated radiation therapy for high-risk and locally advanced prostate cancer: a national population-based study using patient-reported outcomesen
dc.typeArticleen
dc.contributor.departmentDepartment of Health Services Research and Policy, London School of Hygiene and Tropical Medicine; Clinical Effectiveness Unit, Royal College of Surgeons of Englanden
dc.identifier.journalInternational Journal of Radiation Oncology Biology Physicsen
dc.description.noteen]


Files in this item

This item appears in the following Collection(s)

Show simple item record